Europe Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Size

• The Europe hyaluronic acid market for knee osteoarthritis treatment market was valued at USD 646.10 million in 2024 and is expected to reach USD 1,186.80 million by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 7.9%, primarily driven by the anticipated launch of therapies
• The rising prevalence of knee osteoarthritis and the growing preference for minimally invasive treatments are driving demand for hyaluronic acid-based therapies. Additionally, increasing awareness about the benefits of viscosupplementation is further propelling market growth.

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Analysis

• Hyaluronic acid is a naturally occurring substance in the body, particularly in connective tissues, skin, and synovial fluid that lubricates joints. In the context of knee osteoarthritis treatment, hyaluronic acid is utilized as a viscosupplement to improve joint function and alleviate pain. By injecting hyaluronic acid directly into the knee joint, it can enhance the cushioning effect, reduce friction during movement, and promote the regeneration of cartilage, providing relief for individuals suffering from osteoarthritis symptoms. This treatment aims to restore mobility, improve quality of life, and delay the progression of the disease
• Europe emerges as a leading region in the Hyaluronic Acid Market for Knee Osteoarthritis Treatment, driven by its well-established healthcare system and high adoption of advanced, non-surgical joint care options

• For instance, the U.S. shows strong uptake of intra-articular hyaluronic acid injections, supported by growing patient awareness and favorable reimbursement policies

• The region's focus on improving mobility and quality of life for osteoarthritis patients continues to drive innovation and market expansion in hyaluronic acid-based therapies.

Report Scope and Hyaluronic Acid Market for Knee Osteoarthritis Treatment Segmentation

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Trends

“Growing Preference for Minimally Invasive and Targeted Therapies”

• A key trend in the Europe Hyaluronic Acid Market for Knee Osteoarthritis Treatment is the increasing preference for minimally invasive, targeted treatment options.
• Hyaluronic acid injections, also known as viscosupplementation, offer localized pain relief and improved joint mobility without the need for surgical intervention, making them highly attractive to both patients and clinicians

• For instance, single and multi-injection formulations tailored to patient needs are gaining traction, offering flexibility and convenience in treatment regimens

• The trend is further supported by advancements in injection techniques, improved formulation stability, and extended duration of therapeutic effects.
• Additionally, the integration of imaging technologies such as ultrasound-guided injections enhances precision and patient comfort.
• This shift towards non-surgical, effective, and patient-centric treatment options is shaping the future of knee osteoarthritis care and fueling growth in the hyaluronic acid market.

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Dynamics

Driver

“Increasing Prevalence of Knee Osteoarthritis”

• As the Europe population increasingly comprises older adults, the prevalence of osteoarthritis, a degenerative joint condition characterized by the breakdown of cartilage, is expected to grow significantly. This growing demographic trend is particularly alarming since osteoarthritis leads to symptoms such as chronic pain, stiffness, and decreased mobility, which can severely impact the quality of life for individuals affected. The rising incidence of osteoarthritis is prompting a surge in the demand for effective treatment solutions, as many patients are seeking alternatives to invasive surgical options. Hyaluronic acid (HA) injections have emerged as a highly favored minimally invasive treatment option that effectively alleviates symptoms by providing lubrication to the affected joint, thus enhancing joint function and mobility.
• These injections work by supplementing the naturally occurring hyaluronic acid in the synovial fluid, reducing friction between joints and promoting better shock absorption. This dual action not only helps to relieve pain but also improves overall joint health, making HA an appealing choice for both patients and healthcare providers.

For instance,

• In December 2023, NCBI stated that studies continue to illustrate the high prevalence of OA worldwide, with a greater burden among older individuals, women, some racial and ethnic groups, and individuals with lower socioeconomic status. Modifiable risk factors for OA with the strongest evidence are obesity and joint injury
• In November 2024, according an article published by Frontiers, an Indian study reported increasing KOA prevalence rates across different age groups: 19.2% for those under 50, 30.7% for those aged 50–60, 39.7% for those aged 60–70, and 54.1% for those over 70 (23). Another study revealed that both the prevalence and incidence of knee osteoarthritis significantly rise after age 55. Among individuals over 55, the average prevalence rate is 13.2%, with 9.4% for men and 18.0% for women
• The growing awareness of hyaluronic acid's benefits has contributed to its adoption among healthcare professionals and patients alike. As clinical studies and research continue to demonstrate the efficacy of hyaluronic acid in reducing pain and enhancing quality of life for those suffering from knee osteoarthritis, more healthcare providers are incorporating these treatments into their practice. This increasing acceptance, coupled with the rise in osteoarthritis cases, creates a favorable environment for market growth, driving innovation and competition among manufacturers to develop advanced formulations and delivery methods for hyaluronic acid therapies.

Opportunity

“Advancements In Hyaluronic Acid Formulations and Delivery Systems”

• Improved high-molecular-weight and cross-linked hyaluronic acid products provide longer-lasting pain relief and require fewer injections. This appeals to patients seeking effective and convenient solutions for managing their condition. Innovative delivery methods, such as hydrogels and nanoparticle systems, enhance the durability and performance of hyaluronic acid in the joint. These developments meet the rising demand from an aging population. Companies can leverage these technologies to stand out in a competitive market and attract more customers. The focus on reducing treatment frequency while improving patient outcomes strengthens the market’s growth potential. This makes the hyaluronic acid sector for knee osteoarthritis treatment a highly attractive area for investment and expansion

For instance,

• As per IBSA Institut Biochimique SA, Sanofi, Seikagaku Corporation, each company has developed unique formulations to enhance joint lubrication, pain relief, and treatment durability. These innovations focus on improved retention, cross-linking technology, and patient convenience, offering long-lasting symptom relief
• In April 2024 article by sciencedirect highlighted that hyaluronic acid-based liposomes for osteoarthritis drug delivery include surface functionalization after liposome preparation using coupling chemistry or pre-synthesized hyaluronic acid-lipid conjugates through reductive amination. These methods improve biocompatibility, enable simultaneous delivery of various drugs, and enhance control over conjugation, optimizing liposomal systems for effective arthritis treatment

• Advancements in hyaluronic acid formulations and delivery systems significantly enhance the effectiveness and convenience of knee osteoarthritis treatment. By improving product longevity and reducing the frequency of injections, these innovations cater to the growing demand for minimally invasive solutions among an aging population. Companies that embrace these technologies can strengthen their market presence, attract more patients, and capitalize on industry growth. This makes investment in hyaluronic acid-based treatments a strategic opportunity for long-term success in the evolving healthcare landscape.

Restraint/Challenge

“Cost-Related Challenges and Accessibility Concerns For Hyaluronic Acid Therapy In Knee Osteoarthritis”

• Hyaluronic acid (HA) injections for knee osteoarthritis can be prohibitively expensive, particularly when insurance plans either do not cover them fully or exclude them entirely from their benefits. This financial burden often forces patients to pay out-of-pocket, which can be a significant challenge, especially for those with limited financial resources.
• Moreover, multiple injections may be required over time, increasing the cost of treatment. As a result, patients may delay or forgo HA therapy altogether, despite its potential to alleviate pain and improve joint function. The high cost of treatment and lack of insurance coverage often limit accessibility, creating disparities in care. Addressing these financial challenges is vital for making HA therapy more accessible to a wider range of patients, ensuring that more people can benefit from this effective treatment for knee osteoarthritis.

For instance,

• In February 2024, Findings from Pain Physician indicate that Patients receiving HA injections faced significantly higher median costs, especially with multiple injections, compared to those receiving corticosteroid (CS) injections or no injections. Additionally, those requiring total knee arthroplasty (TKA) had higher costs with HA treatment, highlighting the financial barriers associated with this therapy
• As per Sanofi, Enovis and biovico , the high cost of hyaluronic acid (HA) therapy for knee osteoarthritis, such as Synvisc One (USD 232.81) and Biolevox Ha (USD 323.53), limits accessibility. Many patients struggle with affordability, especially without insurance. Lower-cost options, better coverage, and pricing reforms are essential for improving access to these treatments

• The high expense of hyaluronic acid (HA) injections and limited insurance coverage create substantial barriers for many knee osteoarthritis patients. These financial challenges, including the need for multiple injections, often lead patients to delay or abandon HA therapy despite its proven benefits in pain relief and joint function improvement. To improve accessibility and ensure that more individuals can benefit from this treatment, it is essential to address these cost-related issues. Expanding insurance coverage and reducing out-of-pocket expenses will help make HA therapy more accessible, ultimately leading to better care for those suffering from knee osteoarthritis.

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Scope

The market is segmented on the basis type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Regional Analysis

“Germany is the Dominant Country in the Hyaluronic Acid Market for Knee Osteoarthritis Treatment”

• Germany leads the Hyaluronic Acid Market for Knee Osteoarthritis Treatment, supported by its advanced healthcare infrastructure, early adoption of non-surgical joint therapies, and the strong presence of key market players.
• The Germany holds a major market share due to the rising incidence of knee osteoarthritis, growing elderly population, and increasing preference for minimally invasive treatments like intra-articular hyaluronic acid injections.
• Favorable reimbursement policies, well-established regulatory frameworks, and increased healthcare spending further contributes to the market's growth in the region.
• Additionally, the focus on improving patient mobility and quality of life, combined with innovations in HA formulations and delivery techniques, continues to drive market expansion across Europe

“France is Projected to Register the Highest Growth Rate”

• The France region is projected to witness the fastest growth in the Hyaluronic Acid Market for Knee Osteoarthritis Treatment, driven by rapidly evolving healthcare infrastructure, rising awareness of joint health, and increasing demand for minimally invasive treatment options.
• Countries such as Germany, France, U.K. are emerging as key markets due to the growing geriatric population and rising prevalence of knee osteoarthritis.
• France, with its well-established healthcare system and high standards of elderly care, leads in the adoption of advanced HA-based viscosupplementation therapies.
• In France and U.K, large patient populations, increasing healthcare investments, and growing acceptance of non-surgical osteoarthritis treatments are fueling market expansion.
• The presence of both domestic and international HA manufacturers, along with government initiatives to improve access to orthopedic care, further accelerates market growth across the region

Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• LG Chem (South Korea)
• Bioventus LLC (U.S.)
• Seikagaku Corporation (Japan)
• Sanofi (France)
• Anika Therapeutics, Inc. (U.S.)
• IBSA Institut Biochimique SA (Switzerland)
• Viatris (U.S.)
• Zimmer Biomet (U.S.)
• Fidia Farmaceutici S.p.A. (Italy)
• Ferring Pharmaceuticals (Switzerland
• TRB CHEMEDICA SA (Switzerland)
• Hangzhou Singclean Medical Products Co., Ltd. (China)
• Hanmi Pharm. Co., Ltd. (South Korea)
• Virchow Biotech (India)
• Eupraxia Pharmaceuticals (Canada)

Latest Developments in Europe Hyaluronic Acid Market for Knee Osteoarthritis Treatment

• In July 2024, LG Chem entered chinese osteoarthritis treatment market. It Partnered with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China. This allowed the company to enter and expand its portfolio
• In May 2023, Eupraxia Pharmaceuticals announced the completion of the last patient visit in its Phase 2 clinical trial for EP-104IAR, aimed at treating osteoarthritis (OA). The company is on track for top-line data in Q2, with expectations of demonstrating significant pain relief and improved patient function, alongside a promising safety profile
• In March 2025, IBSA has partnered with distributor Lunatus to expand its osteoarticular treatments in Saudi Arabia and the UAE. This strategic collaboration aims to enhance pain management solutions and may extend to other regional countries, addressing the rising demand for advanced care among populations affected by osteoarticular disorders
• In June 2023, Eupraxia Pharmaceuticals announced that the U.S. FDA granted Fast Track designation for EP-104IAR in treating osteoarthritis (OA) of the knee. This designation aims to expedite development and regulatory review, facilitating more frequent interactions with the FDA. The company is advancing its Phase 2 trial with top-line data expected in Q2 2023 

SKU-73866